Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
暂无分享,去创建一个
V. Torri | M. Parmar | J. Ledermann | G. Jayson | I. Floriani | N. Colombo | C. Tropé | G. Kristensen | W. Qian | A. Swart | A. Lamont | B. Du | JF Delaloye | S. Wheeler
[1] E Wiltshaw,et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Rubin,et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Christian,et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Andrew Bottomley,et al. EORTC QLQ-C30 Scoring Manual , 1995 .
[5] David Machin,et al. Survival Analysis: A Practical Approach , 1995 .
[6] E. Partridge,et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.
[7] G. Giaccone,et al. Clinical pharmacology of carboplatin administered in combination with paclitaxel. , 1997, Seminars in oncology.
[8] D. Alberts,et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. , 1998, British Journal of Cancer.
[9] P. Rose,et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Buyse,et al. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer , 1998, The Lancet.
[11] M. Piccart,et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.
[12] F M Muggia,et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] F. Bray,et al. Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.
[14] V. Torri,et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] I. Tannock,et al. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial , 2002, The Lancet.
[16] E. Venkatraman,et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Parmar,et al. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence , 2002, British Journal of Cancer.